KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Accumulated Expenses (2018 - 2025)

Emergent BioSolutions (EBS) has 8 years of Other Accumulated Expenses data on record, last reported at $15.8 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 27.85% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $15.8 million, down 27.85%, while the annual FY2025 figure was $15.8 million, 27.85% down from the prior year.
  • Other Accumulated Expenses reached $15.8 million in Q4 2025 per EBS's latest filing, down from $24.1 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $122.0 million in Q1 2021 and bottomed at $11.1 million in Q1 2025.
  • Average Other Accumulated Expenses over 5 years is $40.2 million, with a median of $24.9 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 1505.26% in 2021, then crashed 79.84% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $72.9 million in 2021, then tumbled by 37.04% to $45.9 million in 2022, then dropped by 28.76% to $32.7 million in 2023, then crashed by 33.03% to $21.9 million in 2024, then fell by 27.85% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $15.8 million in Q4 2025, $24.1 million in Q3 2025, and $13.6 million in Q2 2025.